Open AccessPhase I/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Children’s Oncology Group
Author(s) -
Todd M. Cooper,
Michael J. Absalon,
Todd A. Alonzo,
Robert B. Gerbing,
Kasey J. Leger,
Betsy Hirsch,
Jessica A. Pollard,
Bassem I. Razzouk,
Richard Aplenc,
E. Anders Kolb
Publication year - 2020
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.19.03306
Subject(s) - medicine , cytarabine , fludarabine , neutropenia , absolute neutrophil count , granulocyte colony stimulating factor , febrile neutropenia , gastroenterology , regimen , phases of clinical research , flag (linear algebra) , myeloid leukemia , surgery , chemotherapy , cyclophosphamide , mathematics , pure mathematics , algebra over a field
Effective regimens are needed for children with relapsed acute myeloid leukemia (AML). AAML1421 is a phase I/II study of CPX-351, a liposomal preparation of daunorubicin and cytarabine. AAML1421 sought to determine the recommended phase II dose (RP2D) of CPX-351 and the response rate after up to 2 cycles of therapy.